Ahmed Afifi

Dr. Ahmed Afifi


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
AMAhmed Marey
Ahmed Marey
SMSaba Mehrtabar
Saba Mehrtabar
AAAhmed Afifi
Ahmed Afifi
BPBasudha Pal
Basudha Pal
ATArcadia Trvalik
Arcadia Trvalik
MUMuhammad Umair
Muhammad Umair
Objectives: The aim of this study was to synthesize current evidence on artificial intelligence (AI) adoption in cardiovascular imaging across low- and middle-income countries (LMICs), highlighting diagnostic performance, implementation barriers, and potential solutions. Methods: We conducted a systematic review of PubMed, Embase, Cochrane Library, Web of Science, and Scopus for studies evaluating AI-based echocardiography, cardiac CT, or cardiac MRI in LMICs. Articles were screened according to PRISMA guidelines, and data on diagnostic outcomes, challenges, and enabling factors were extracted and narratively synthesized. Results: Twelve studies met the inclusion criteria. AI-driven methods frequently surpassed 90% accuracy in detecting coronary artery disease, rheumatic heart disease, and left ventricular hypertrophy, often enabling task shifting to non-expert operators. Challenges included limited dataset diversity, operator dependence, infrastructure constraints, and ethical considerations. Insights from high-income countries, such as automated segmentation and accelerated imaging, suggest potential for broader AI integration in cardiac MRI and CT. Conclusions: AI holds promise for enhancing cardiovascular care in LMICs by improving diagnostic accuracy and workforce efficiency. However, multi-center data sharing, targeted training, reliable infrastructure, and robust governance are essential for sustainable adoption. This review underscores AI’s capacity to bridge resource gaps in LMICs, offering practical pathways for future research, clinical practice, and policy development in global cardiovascular imaging.

11 November 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
MDMuhiddin Dervis
Muhiddin Dervis
AMAhmed Marey
Ahmed Marey
STShiva Toumaj
Shiva Toumaj
RQRuaa Mustafa Qafesha
Ruaa Mustafa Qafesha
DMDoaa Mashaly
Doaa Mashaly
MUMuhammad Umair
Muhammad Umair
Magnetic Particle Imaging (MPI) is a new type of tracer-based imaging that has great spatial and temporal resolution, does not require ionizing radiation, and can see deep into tissues by directly measuring the nonlinear magnetization response of superparamagnetic iron oxide nanoparticles (SPIONs). Unlike Magnetic Resonance Imaging (MRI) or Computed Tomography (CT), MPI has very high contrast and quantitative accuracy, which makes it perfect for use in dynamic cardiovascular applications. This study presents a full picture of the most recent changes in cardiac MPI, such as the physics behind Field-Free Point (FFP) and Field-Free Line (FFL) encoding, new ideas for tracer design, and important steps in the evolution of scanner hardware. We discuss the clinical relevance of cardiac MPI in visualizing myocardial perfusion, quantifying blood flow, and guiding real-time interventions. A hybrid imaging workflow, which improves anatomical detail and functional assessment, is utilized to explore the integration of MPI with complementary modalities, particularly MRI. By consolidating recent preclinical breakthroughs and highlighting the roadmap toward human-scale implementation, this article underscores the transformative potential of MPI in cardiac diagnostics and image-guided therapy.

29 May 2026 in Bioengineering
Verified
Journal Article
Open access
PDF file
STShiva Toumaj
Shiva Toumaj
AAAhmed Afifi
Ahmed Afifi
MDMuhiddin Dervis
Muhiddin Dervis
DMDoaa Mashaly
Doaa Mashaly
AAAbdallah Abudraz
Abdallah Abudraz
MUMuhammad Umair
Muhammad Umair
Background: Magnetic particle imaging (MPI) is an emerging, tracer-based modality that directly detects superparamagnetic iron oxide nanoparticles (SPIONs) with exceptional sensitivity, quantitative signal behavior, and full immunity to air–tissue susceptibility artifacts. These features make MPI particularly well-suited for pulmonary imaging, where traditional techniques such as computed tomography (CT), magnetic resonance imaging (MRI), and nuclear medicine-based ventilation/perfusion (V/Q) imaging are limited by radiation exposure, low contrast, and motion-related signal degradation. Objective: This review synthesizes the current state of MPI for lung imaging, with emphasis on its physical principles, tracer development, preclinical applications, and its potential role in assessing pulmonary perfusion, vascular integrity, inflammation, and therapeutic responses. Methods: A systematic evaluation of preclinical studies was performed across three major application domains: pulmonary perfusion mapping, cell tracking and therapeutic monitoring, and vascular injury and permeability assessment. Study designs, SPION formulations, MPI acquisition strategies, and validation methods, including histopathology, biodistribution, broncho-alveolar lavage fluid (BALF) analysis, and Evans Blue assays, were examined to characterize methodological consistency and imaging performance. Results: MPI consistently demonstrated high-contrast, quantitative visualization of pulmonary blood flow, endothelial barrier disruption, inflammatory signaling, and transplanted or inhaled cell populations. Tracer engineering played a critical role: macroaggregated albumin superparamagnetic iron oxide nanoparticles (MAA-SPIONs) enabled capillary-level perfusion mapping, LS-008 improved temporal resolution and vascular delineation, Synomag/Synomag-D allowed quantification of vascular leakage in acute and chronic lung injury, and vascular cell adhesion molecule-1 (VCAM-1)-targeted probes provided molecular-level assessment of inflammation. Hybrid MPI-CT and MPI-MRI approaches further enhanced anatomic localization and enabled accurate pulmonary blood volume (PBV) estimation. Across studies, MPI measurements showed strong agreement with established biological assays and remained free of the artifacts that limit CT and MRI in the lung. Conclusions: Preclinical evidence demonstrates that MPI is a robust, radiation-free, and quantitatively precise modality for functional and molecular lung imaging. Its ability to map perfusion, track therapeutic agents, and noninvasively quantify vascular permeability positions MPI as a promising future alternative or complement to CT, MRI, and nuclear medicine for pulmonary assessment. Continued tracer optimization, system scaling, and clinical validation are key steps toward translating MPI into routine clinical use.